These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37524010)

  • 1. Synthesis, biological evaluation and docking studies of silicon incorporated diarylpyrroles as MmpL3 inhibitors: An effective strategy towards development of potent anti-tubercular agents.
    Vasudevan N; Motiwala Z; Ramesh R; Wagh SB; Shingare RD; Katte R; Anand A; Choudhary S; Kumar A; Gokhale RS; Kulkarni KA; Reddy DS
    Eur J Med Chem; 2023 Nov; 259():115633. PubMed ID: 37524010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.
    Ramesh R; Shingare RD; Kumar V; Anand A; B S; Veeraraghavan S; Viswanadha S; Ummanni R; Gokhale R; Srinivasa Reddy D
    Eur J Med Chem; 2016 Oct; 122():723-730. PubMed ID: 27476117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A piperidinol-containing molecule is active against
    Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
    J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
    [No Abstract]   [Full Text] [Related]  

  • 4. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
    Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
    Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-Pot Synthesis of Novel Hydrazono-1,3-Thıazolıdın-4-One Derivatives as Anti-HIV and Anti-Tubercular Agents: Synthesıs, Bıologıcal Evaluatıon, Molecular Modelling and Admet Studıes.
    Pasha MA; Mondal S; Panigrahi N; Shetye G; Ma R; Franzblau SG; Zheng YT; Murugesan S
    Curr HIV Res; 2022; 20(3):255-271. PubMed ID: 35549861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specifically Targeting Mtb Cell-Wall and TMM Transporter: The Development of MmpL3 Inhibitors.
    Luo Q; Duan H; Yan H; Liu X; Peng L; Hu Y; Liu W; Liang L; Shi H; Zhao G; Hu J
    Curr Protein Pept Sci; 2021 Oct; 22(4):290-303. PubMed ID: 33882806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore based virtual screening & molecular docking approach for identification of mycobacterial membrane protein large 3 (MmpL3) inhibitors.
    Dhulap A; Banerjee P
    J Biomol Struct Dyn; 2023 Dec; 41(20):11062-11077. PubMed ID: 36571432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of anti-mycobacterial drug leads that target the mycolic acid transporter MmpL3.
    Hu T; Yang X; Liu F; Sun S; Xiong Z; Liang J; Yang X; Wang H; Yang X; Guddat LW; Yang H; Rao Z; Zhang B
    Structure; 2022 Oct; 30(10):1395-1402.e4. PubMed ID: 35981536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-Resistant Tuberculosis.
    Zhao H; Gao Y; Li W; Sheng L; Cui K; Wang B; Fu L; Gao M; Lin Z; Zou X; Jackson M; Huang H; Lu Y; Zhang D
    J Med Chem; 2022 Aug; 65(15):10534-10553. PubMed ID: 35915958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents.
    Modi P; Patel S; Chhabria M
    Bioorg Chem; 2019 Jun; 87():240-251. PubMed ID: 30908967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
    Li W; Upadhyay A; Fontes FL; North EJ; Wang Y; Crans DC; Grzegorzewicz AE; Jones V; Franzblau SG; Lee RE; Crick DC; Jackson M
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6413-23. PubMed ID: 25136022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection.
    Poce G; Bates RH; Alfonso S; Cocozza M; Porretta GC; Ballell L; Rullas J; Ortega F; De Logu A; Agus E; La Rosa V; Pasca MR; De Rossi E; Wae B; Franzblau SG; Manetti F; Botta M; Biava M
    PLoS One; 2013; 8(2):e56980. PubMed ID: 23437287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.
    La Rosa V; Poce G; Canseco JO; Buroni S; Pasca MR; Biava M; Raju RM; Porretta GC; Alfonso S; Battilocchio C; Javid B; Sorrentino F; Ioerger TR; Sacchettini JC; Manetti F; Botta M; De Logu A; Rubin EJ; De Rossi E
    Antimicrob Agents Chemother; 2012 Jan; 56(1):324-31. PubMed ID: 22024828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational design of MmpL3 inhibitors for tuberculosis therapy.
    Chaitra R; Gandhi R; Jayanna N; Satyanath S; Pavadai P; Murahari M
    Mol Divers; 2023 Feb; 27(1):357-369. PubMed ID: 35477825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis.
    Umare MD; Khedekar PB; Chikhale RV
    ChemMedChem; 2021 Oct; 16(20):3136-3148. PubMed ID: 34288519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Structural Elucidation of Novel Benzothiazole Derivatives as Anti-tubercular Agents: In-silico Screening for Possible Target Identification.
    Venugopala KN; Chandrashekharappa S; Pillay M; Bhandary S; Kandeel M; Mahomoodally FM; Morsy MA; Chopra D; Aldhubiab BE; Attimarad M; Alwassil OI; Harsha S; Mlisana K; Odhav B
    Med Chem; 2019; 15(3):311-326. PubMed ID: 29968540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro bioevaluation and docking study of dihydrosphingosine and ethambutol analogues against sensitive and multi-drug resistant Mycobacterium tuberculosis.
    Linhares LA; Dos Santos Peixoto A; Correia de Sousa LA; Lucena Laet JP; da Silva Santos AC; Alves Pereira VR; Carneiro Neves MM; Ferreira LFGR; Hernandes MZ; de la Vega J; Pereira-Neves A; San Feliciano A; Olmo ED; Schindler HC; Montenegro LML
    Eur J Med Chem; 2023 Oct; 258():115579. PubMed ID: 37399709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents.
    Wen Y; Lun S; Jiao Y; Zhang W; Liu T; Yang F; Tang J; Bishai WR; Yu LF
    Eur J Med Chem; 2023 Jul; 255():115351. PubMed ID: 37116266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered drug efflux under iron deprivation unveils abrogated MmpL3 driven mycolic acid transport and fluidity in mycobacteria.
    Pal R; Hameed S; Fatima Z
    Biometals; 2019 Feb; 32(1):49-63. PubMed ID: 30430296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multi-target aspect of an MmpL3 inhibitor: The BM212 series of compounds bind EthR2, a transcriptional regulator of ethionamide activation.
    Moorey AR; Cabanillas A; Batt SM; Ghidelli-Disse S; Urones B; Sanz O; Lelievre J; Bantscheff M; Cox LR; Besra GS
    Cell Surf; 2021 Dec; 7():100068. PubMed ID: 34888432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.